139 related articles for article (PubMed ID: 36419844)
21.
Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].
Cai TY; Zhu ZP; Xu CR; Ji X; Lv TD; Guo ZK; Lin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):628-635. PubMed ID: 35950384
[TBL] [Abstract][Full Text] [Related]
23. Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma.
Guo H; Jiang S; Sun H; Shi B; Li Y; Zhou N; Zhang D; Guo H
Dis Markers; 2022; 2022():9443407. PubMed ID: 35299868
[TBL] [Abstract][Full Text] [Related]
24. ENO2 Promotes Colorectal Cancer Metastasis by Interacting with the LncRNA CYTOR and Activating YAP1-Induced EMT.
Lv C; Yu H; Wang K; Chen C; Tang J; Han F; Mai M; Ye K; Lai M; Zhang H
Cells; 2022 Aug; 11(15):. PubMed ID: 35954207
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of
Wang T; Xie F; Li YH; Liang B
Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
[TBL] [Abstract][Full Text] [Related]
26. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
[TBL] [Abstract][Full Text] [Related]
27. Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma.
Yuan X; He Y; Luo C; Wang W
Invest New Drugs; 2022 Apr; 40(2):232-244. PubMed ID: 34633577
[TBL] [Abstract][Full Text] [Related]
28. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
29. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
31. The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma.
Zhou Y; Wang X; Zhang W; Liu H; Liu D; Chen P; Xu D; Liu J; Li Y; Zeng G; Li M; Wu Z; Zhang Y; Wang X; DiSanto ME; Zhang X
Front Oncol; 2021; 11():630706. PubMed ID: 33968730
[TBL] [Abstract][Full Text] [Related]
32. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
[TBL] [Abstract][Full Text] [Related]
33. Glycolysis-Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma.
Zhang Y; Chen M; Liu M; Xu Y; Wu G
Oxid Med Cell Longev; 2021; 2021():6699808. PubMed ID: 33564363
[TBL] [Abstract][Full Text] [Related]
34. Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma.
Dong Y; Ma WM; Yang W; Hao L; Zhang SQ; Fang K; Hu CH; Zhang QJ; Shi ZD; Zhang WD; Fan T; Xia T; Han CH
BMC Cancer; 2021 Oct; 21(1):1135. PubMed ID: 34688260
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Enolase Gene Family in Colon Cancer.
Pan X; Wu H; Chen G; Li W
Med Sci Monit; 2020 Jul; 26():e922980. PubMed ID: 32703926
[TBL] [Abstract][Full Text] [Related]
36. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
37. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
Qiu X; Gu Y; Ni Y; Li Q
Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
[TBL] [Abstract][Full Text] [Related]
38. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
[TBL] [Abstract][Full Text] [Related]
39. SLC22A8: An indicator for tumor immune microenvironment and prognosis of ccRCC from a comprehensive analysis of bioinformatics.
Xu K; Wu Y; Chi H; Li Y; She Y; Yin X; Liu X; He B; Li X; Du H
Medicine (Baltimore); 2022 Sep; 101(37):e30270. PubMed ID: 36123895
[TBL] [Abstract][Full Text] [Related]
40. Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma.
Gong Z; Xie J; Chen L; Tang Q; Hu Y; Xu A; Wang Z
Channels (Austin); 2022 Dec; 16(1):84-96. PubMed ID: 35389815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
